Innovative Clinical Research Solutions
- Since 1991 -
Full-Service, Dedicated, Data Driven – from “Thought to Finish”, Every Trial, Every Time.
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients Preliminary results from phase 1 clinical trial of WP1220 for treatment of cutaneous T-cell lymphoma (“CTCL”); supports phase 2 study. “For years, p-STAT3 (the activated form of STAT3) has been considered an ‘undruggable’